CL2016001895A1 - Compuestos - Google Patents

Compuestos

Info

Publication number
CL2016001895A1
CL2016001895A1 CL2016001895A CL2016001895A CL2016001895A1 CL 2016001895 A1 CL2016001895 A1 CL 2016001895A1 CL 2016001895 A CL2016001895 A CL 2016001895A CL 2016001895 A CL2016001895 A CL 2016001895A CL 2016001895 A1 CL2016001895 A1 CL 2016001895A1
Authority
CL
Chile
Prior art keywords
compounds
pirazolo
pirimidin
pirrolo
amina
Prior art date
Application number
CL2016001895A
Other languages
English (en)
Inventor
Xiao Ding
Qian Liu
Yingxia Sang
Luigi Piero Stasi
Zehong Wan
Baowei Zhao
Colin Michael Edge
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of CL2016001895A1 publication Critical patent/CL2016001895A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPUESTOS DERIVADOS DE PIRAZOLO PIRROLO[2,3-D]PIRIMIDIN-2-AMINA, COMO INHIBIDORES DE LA ACTIVIDAD DE LAS CINASAS LRRK2; COMPOSICIÓN FARMACÉUTICA; Y SU USO PARA EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON.
CL2016001895A 2014-01-29 2016-07-26 Compuestos CL2016001895A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2014000139 2014-01-29

Publications (1)

Publication Number Publication Date
CL2016001895A1 true CL2016001895A1 (es) 2016-12-09

Family

ID=53756224

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001895A CL2016001895A1 (es) 2014-01-29 2016-07-26 Compuestos

Country Status (20)

Country Link
US (2) US10087186B2 (es)
EP (1) EP3099695B1 (es)
JP (1) JP6422986B2 (es)
KR (1) KR20160106622A (es)
CN (1) CN105940004B (es)
AU (2) AU2015210593A1 (es)
CA (1) CA2937431A1 (es)
CL (1) CL2016001895A1 (es)
CR (1) CR20160348A (es)
DO (2) DOP2016000195A (es)
EA (1) EA029774B1 (es)
ES (1) ES2802174T3 (es)
IL (1) IL246579B (es)
MA (1) MA39219B1 (es)
MX (1) MX367370B (es)
PE (1) PE20161443A1 (es)
PH (1) PH12016501307A1 (es)
SG (1) SG11201605342UA (es)
UA (1) UA118369C2 (es)
WO (1) WO2015113452A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10339791B2 (en) 2007-06-12 2019-07-02 Icontrol Networks, Inc. Security network integrated with premise security system
US9815841B2 (en) 2014-01-29 2017-11-14 Glaxosmithkline Intellectual Property Development Limited Compounds
KR20160106622A (ko) 2014-01-29 2016-09-12 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 화합물
CN105153131B (zh) * 2015-09-21 2017-10-17 马彦丽 一种在护理上治疗人神经胶质瘤的药物组合物
CN105348270B (zh) * 2015-11-09 2018-01-09 吕显艳 一种防治牙体牙髓感染的药物组合物
WO2017087905A1 (en) * 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
CN108934162A (zh) 2015-12-16 2018-12-04 南方研究所 吡咯并嘧啶化合物、作为激酶lrrk2抑制剂的用途及其制备方法
CN105418616B (zh) * 2015-12-26 2018-01-12 山东大学 一种含有 4‑氨基吡唑结构的jak 激酶抑制剂及其制备方法和应用
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
IL299415B2 (en) 2016-06-16 2025-09-01 Denali Therapeutics Inc Pyrimidine-2-ylamino-1H-pyrazoles as LRRK2 inhibitors for use in the treatment of neurodegenerative disorders
CA3050156A1 (en) * 2017-01-25 2018-08-02 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2018155916A2 (ko) * 2017-02-22 2018-08-30 재단법인 대구경북첨단의료산업진흥재단 피롤로-피리미딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
AU2018239798B2 (en) * 2017-03-23 2020-08-27 Daegu Gyeongbuk Institute Of Science And Technology Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases
MX2020005866A (es) * 2017-12-05 2020-09-09 Oscotec Inc Derivado de pirrolo(pirazolo)pirimidina como inhibidor de lrrk2.
CN108715834B (zh) * 2018-06-01 2021-09-14 天晴干细胞股份有限公司 一种富含cd41+、cd81+微囊的血小板裂解液制备方法
WO2020036437A1 (ko) * 2018-08-16 2020-02-20 재단법인 대구경북첨단의료산업진흥재단 치환된 헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
EP3856188B1 (en) * 2018-09-25 2023-06-21 Cardurion Pharmaceuticals, Inc. Aminopyrimidine compound
CA3168211A1 (en) 2019-01-18 2020-07-23 Voronoi Co., Ltd. Pyrrolopyridine derivative and use thereof for preventing or treating protein kinase related disease
CZ308800B6 (cs) * 2019-02-12 2021-05-26 Univerzita Palackého v Olomouci Heterocyklické dusíkaté deriváty purinu, farmaceutické přípravky obsahující tyto deriváty a jejich použití při neuroprotekci
CN114426542B (zh) * 2020-10-29 2023-06-30 苏州亚宝药物研发有限公司 取代的二芳基胺化合物及其药物组合物、制备方法和用途
CA3195193A1 (en) 2020-10-29 2022-05-05 Peter H. Fuller N-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
KR20220081631A (ko) 2020-12-09 2022-06-16 보로노이 주식회사 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
WO2023073013A1 (en) 2021-10-27 2023-05-04 H. Lundbeck A/S Lrrk2 inhibitors
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
AR130483A1 (es) 2022-09-15 2024-12-11 H Lundbeck As Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028480A2 (en) 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP2316927B1 (en) 2004-10-21 2014-11-05 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Kaspp (lrrk2) gene, its production and use for the detection and treatment of neurodegenerative disorders
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
NO323175B1 (no) 2004-12-23 2007-01-15 Jan O Aasly Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme
US20080004295A1 (en) 2005-10-13 2008-01-03 Gore Paul M Novel compounds
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
US8158636B2 (en) 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US20090325964A1 (en) 2008-05-23 2009-12-31 Wyeth Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression
JP5918693B2 (ja) 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
SG179120A1 (en) * 2009-09-29 2012-05-30 Glaxo Group Ltd Novel compounds
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
WO2012045195A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
SI2638031T1 (en) * 2010-11-10 2018-02-28 Genentech, Inc. Pyrazole aminopyrimidine derivatives as LRRK2 modulators
US20140031547A1 (en) 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
AU2012244550C1 (en) * 2011-04-21 2017-06-22 Origenis Gmbh Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
ES2575710T3 (es) * 2011-09-22 2016-06-30 Pfizer Inc Derivados de pirrolopirimidina y purina
BR112014012822A8 (pt) * 2011-11-30 2017-07-11 Hoffmann La Roche Radioligantes rotulados com flúor-18 e carbono-11 para imagiologia por tomografia por emissão de pósitrons (pet) para lrrk2
GB201204985D0 (en) * 2012-03-21 2012-05-02 Genentech Inc Compounds
WO2013164321A1 (en) 2012-05-03 2013-11-07 F. Hoffmann-La Roche Ag Pyrazole aminopyrimidine derivatives as lrrk2 modulators
BR112014027117B1 (pt) 2012-05-03 2022-09-06 Genentech, Inc Derivados de pirazol aminopirimidina como moduladores de lrrk2, seus usos, e composição
MD20140130A2 (ro) 2012-06-29 2015-04-30 Pfizer Inc. 4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2
KR20160106622A (ko) 2014-01-29 2016-09-12 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 화합물
US9815841B2 (en) 2014-01-29 2017-11-14 Glaxosmithkline Intellectual Property Development Limited Compounds

Also Published As

Publication number Publication date
US10618901B2 (en) 2020-04-14
CN105940004B (zh) 2018-02-02
DOP2019000010A (es) 2019-03-15
CA2937431A1 (en) 2015-08-06
EP3099695B1 (en) 2020-04-08
AU2018200277B2 (en) 2019-09-26
MX367370B (es) 2019-08-16
US10087186B2 (en) 2018-10-02
EP3099695A1 (en) 2016-12-07
DOP2016000195A (es) 2016-10-31
AU2018200277A1 (en) 2018-02-01
CN105940004A (zh) 2016-09-14
JP6422986B2 (ja) 2018-11-14
EA029774B1 (ru) 2018-05-31
UA118369C2 (uk) 2019-01-10
PH12016501307B1 (en) 2016-08-15
CR20160348A (es) 2017-04-28
SG11201605342UA (en) 2016-08-30
PE20161443A1 (es) 2017-01-06
US20170015668A1 (en) 2017-01-19
MA39219B1 (fr) 2018-11-30
PH12016501307A1 (en) 2016-08-15
WO2015113452A1 (en) 2015-08-06
EA201691514A1 (ru) 2016-12-30
IL246579B (en) 2019-05-30
EP3099695A4 (en) 2017-07-12
ES2802174T3 (es) 2021-01-15
MX2016009893A (es) 2016-10-31
US20180354956A1 (en) 2018-12-13
AU2015210593A1 (en) 2016-07-07
KR20160106622A (ko) 2016-09-12
JP2017504631A (ja) 2017-02-09
MA39219A1 (fr) 2017-09-29
IL246579A0 (en) 2016-08-31

Similar Documents

Publication Publication Date Title
UY36544A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
MX2015003140A (es) Formulaciones de enzalutamida.
MX382033B (es) Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
JO3512B1 (ar) مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
MX2016010105A (es) Derivados de nucleosido sustituidos con 4´ -difluorometilo como inhibidores de la replicacion de arn de la infuenza.
CR20170478A (es) Compuestos novedosos
UY36175A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
BR112015019508A8 (pt) formas sólidas de um inibidor de cdk4/6 seletivo
CL2014000543A1 (es) Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer.
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
MX392130B (es) Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades.
MX373129B (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CL2015002060A1 (es) Compuestos.
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
UY35747A (es) Derivados sustituidos de fenilalanina
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.